MedTrace Logo

Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana

NCT04852185 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23000

Last updated 2024-03-08

No results posted yet for this study

Summary

A cluster-randomised controlled Phase IV trial (cRCT) assessing the impact of a Vi-Polysaccharide conjugate vaccine in preventing typhoid infection in Asante Akim, Ghana (TyVEGHA) with a primary endpoint of determining the total protection conferred by single-dose vaccination with Vi-TT against blood culture-confirmed symptomatic S. Typhi infection in the intervention vaccine clusters, compared with the control vaccine clusters.

Conditions

  • Typhoid Fever

Interventions

BIOLOGICAL

Vi-TT

Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.

BIOLOGICAL

MCV-A vaccine

Single-dose of MCV-A vaccine (a meningococcal vaccine)

Sponsors & Collaborators

  • Kwame Nkrumah University of Science and Technology

    collaborator OTHER

  • University of Cambridge

    collaborator OTHER

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • Fondation Mérieux

    collaborator OTHER

  • University of Maryland, Baltimore

    collaborator OTHER

  • International Vaccine Institute

    lead OTHER

Principal Investigators

  • Florian Marks, PhD · University of Cambridge

  • Ellis Owusu Dabo, PhD · Kwame Nkrumah University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
9 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-24
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Ghana

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04852185 on ClinicalTrials.gov